QIAGEN announces winners of 2018 Microbiome Awards competition
Oct 17 2018

QIAGEN announces winners of 2018 Microbiome Awards competition

Two extraordinary young scientists honored with prizes and more than $100,000 in support for research into the impacts of microbial communities on human health

Hilden, Germany, and Germantown, Maryland, October 17, 2018 – QIAGEN today announced the winners of its fifth annual 2018 Microbiome Awards, a competition for outstanding researchers working on diverse aspects of the microbiome. The prize package totals more than $100,000. This year’s­ winner in the Ph.D. Scientist category is Dr. Hannah Wardill of The University of Adelaide, Australia, and The University Medical Centre Groningen, the Netherlands. In the Ph.D. Student category the winner is Marsha Wibowo of Harvard Medical School, who will carry out her project at Harvard’s Joslin Diabetes Center.

“Studies of the microbiome hold great promise for providing insights that lead to novel strategies for prevention and treatment of disease. As the global leader in Sample to Insight solutions for molecular testing, QIAGEN sponsors this competition with high-level, independent judging to encourage researchers in some of the most innovative explorations of how microbial communities influence our environment and health,” said Dr. Thomas Schweins, Senior Vice President, Life Science Business Area, for QIAGEN. “We are pleased to honor these two outstanding young scientists and provide support for their research. The Microbiome Awards are the largest research awards program focusing on this important field.”

Dr. Wardill’s ongoing research aims to apply knowledge in in the field of oncogastroenterology to provide precision medicine to children with cancer. By exploiting the emerging link between the microbiome and cancer treatment, Dr. Wardill is developing a microbial algorithm to predict treatment response, thus enabling implementation of personalized treatment strategies. This approach will enable proactive delivery of supportive care measures, help avoid ineffective treatments and provide an opportunity to enhance the outcomes of cancer treatment by modulating the microbiome. Dr. Wardill will receive a research package of QIAGEN products and services totaling $80,000.

“It seems the microbiome is now linked with almost every disease imaginable, and with this comes an increasingly large pool of scientists tackling similar research questions,” Dr. Wardill said. “To have my research recognized on this scale is extremely validating, and reinforces the importance and rigor of my work. I am extremely proud and humbled to be recognized in the Microbiome Awards.”

Ms. Wibowo’s research project will examine the role of extinction events in the gut microbiome during the progression of obesity and type 2 diabetes. She will receive a research package of QIAGEN products and services worth more than $20,000.

The judging panel for the Microbiome Awards consisted of independent, distinguished scientists from various institutions and universities, who are currently leading the field of microbiome research. The judges included Dr. Elisabeth Bik of uBiome; Dr. David Coil, University of California, Davis; Dr. Daryl Gohl, the University of Minnesota Genomics Center Innovation Lab and CoreBiome; Dr. Emily Hollister, Diversigen; and Dr. Christopher Stewart, Newcastle University. For more information about the projects of the Microbiome Award winners, please visit https://mobio.com/winners.

QIAGEN’s Leadership in Microbiome Research

As an industry pioneer of research solutions for sample preparation, in-depth molecular analyses and data interpretation, QIAGEN is a renowned supporter of microbiome research initiatives worldwide. Products from the microbiome portfolio are currently used and recommended by international consortia like the Human Microbiome Project, the Earth Microbiome Project and the MetaSUB Consortium.


QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of June 30, 2018, QIAGEN employed approximately 4,800 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).


Share this page